NCT05566054 is a Phase 2 clinical trial of Chidamide in Acute Monocytic Leukemia, sponsored by The First Affiliated Hospital of Soochow University.

Who is sponsoring NCT05566054?

NCT05566054 is sponsored by The First Affiliated Hospital of Soochow University.

What drugs are being tested in NCT05566054?

Interventions in NCT05566054: Chidamide, Azacitidine, Venetoclax.

What condition does NCT05566054 study?

NCT05566054 studies Acute Monocytic Leukemia, Newly Diagnosed.

Is NCT05566054 still recruiting?

NCT05566054 is currently recruiting now. Last updated 21 November 2025.

Last reviewed 2025-11-21 · How we verify

NCT05566054

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

Recruiting now Phase 2 Last updated 21 November 2025

What this trial tests

Phase 2 trial testing Chidamide in Acute Monocytic Leukemia in 92 participants. Currently enrolling.

Timeline

1 March 2022

Primary endpoint
30 September 2026

30 September 2026

Quick facts

Lead sponsor	The First Affiliated Hospital of Soochow University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	92
Start date	1 March 2022
Primary completion	30 September 2026
Estimated completion	30 September 2026
Sites	1 location across China

Drugs / interventions tested

Chidamide — full drug profile →
Azacitidine (azacitidine) — full drug profile →
Venetoclax (venetoclax) — full drug profile →

Conditions studied

Acute Monocytic Leukemia — all drugs for Acute Monocytic Leukemia →
Newly Diagnosed — all drugs for Newly Diagnosed →

Sponsor

The First Affiliated Hospital of Soochow University

Who can join

18 and older, any sex, with Acute Monocytic Leukemia or Newly Diagnosed. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to investigate the therapeutic efficacy and side effect of venetoclax, azacytidine combined with chidamide for newly diagnosed acute monocytic leukemia patients that are ineligible for intensive chemotherapy

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular Era.
Chatzilygeroudi T, Karantanos T, Pappa V. · · 2025 · cited 9× · PMID 40361510 · DOI 10.3390/cancers17091586
HDAC3-YY1-RAB5A axis remodels AML-supportive niche by modulating mitochondrial homeostasis in bone marrow stromal cells.
He C, Xiong Y, Zeng Y, Feng J, et al · · 2025 · cited 2× · PMID 40623992 · DOI 10.1038/s41419-025-07777-9

Verify or expand the search:

Other trials of Chidamide

Trials testing the same drug.

NCT07493109 — Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP · Phase 3 · recruiting
NCT07493148 — Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL · Phase 2 · recruiting
NCT07415980 — Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients · Phase 1, PHASE2 · not yet recruiting
NCT07507318 — Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission · Phase 2 · not yet recruiting
NCT07320963 — Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for Acute Monocytic Leukemia

Currently open trials in the same condition.

NCT07512700 — Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia · Phase 2 · recruiting
NCT06950034 — A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) · Phase 1 · recruiting
NCT06504459 — Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment · Phase 2 · recruiting

Other The First Affiliated Hospital of Soochow University trials

Trials by the same sponsor.

NCT07350863 — U69-CART-Cells For R/R T-ALL · Phase 1 · recruiting
NCT06985498 — Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL · Phase 2 · not yet recruiting
NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
NCT07500753 — A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients · NA · recruiting
NCT07511426 — U96-CAR-T-Cells For R/R B-ALL · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05566054 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Soochow University
Last refreshed: 21 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05566054.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing